Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+)
NCT ID: NCT04351919
Last Updated: 2020-08-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
2020-05-05
2020-07-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Hydroxychloroquine and Azithromycin for Patients With Moderate to Severe COVID-19
NCT04329572
PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds
NCT04351191
Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection
NCT04341727
Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19
NCT04322396
Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment
NCT04353336
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HCQ Arm
Hydroxychloroquine
400mg per day during 10 days
Azithromycin
500 mg per day during 5 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hydroxychloroquine
400mg per day during 10 days
Azithromycin
500 mg per day during 5 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Qt\<500ms
* no severity criteria
* pauci-symptomatique patients
* signed consent form
Exclusion Criteria
* severity criteria
* known allegies to macrolides and HCQ
* Treated with HCQ within 1 month prior to inclusion
* hepatitis insufficiency
* Renal insufficiency
* treatment no indicated with azithro and HCQ
* hypovolemia
* complete brach block
* retinopathia
* psoriasis
* pregnancy or breastfeeding
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eshmoun Clinical Research Center
NETWORK
Dacima Consulting
OTHER
Abderrahmane Mami Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Jalila Ben Khelil
Head of department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eshmoun Clinical Research Centre/ Hôpital Abderrahmen Mami-Ariana
Tunis, , Tunisia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ECC2020-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.